Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01192503 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Rasagiline in Restless Legs Syndrome
A Phase 2 study, sponsored by University of Virginia.
- Terminated
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT01192503: Clinical Trial Phase 2 study, sponsored by University of Virginia.
NCT01192503 is a Phase 2 study that was terminated before completion, run by University of Virginia. The registered enrollment target is 52 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01192503, a Phase 2 study, was terminated before completion, sponsored by University of Virginia.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if rasagiline improves RLS symptoms. We also want to make sure rasagiline is safe to give people with RLS.
Primary Outcome
The IRLS is a 10-question scale that contains questions about both the frequency and severity of RLS symptoms, as well as secondary aspects such as sleep quality and daytime tiredness.
Interventions
- DRUG rasagiline
- DRUG placebo (sugar pill)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2010-09 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Why NCT01192503 stopped before completion
NCT01192503 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 2 interventions - of which rasagiline is the first listed.
NCT01192503 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01192503 about?
NCT01192503 is a clinical study titled "Safety and Efficacy of Rasagiline in Restless Legs Syndrome". The purpose of this study is to find out if rasagiline improves RLS symptoms. We also want to make sure rasagiline is safe to give people with RLS.
What is the current status of trial NCT01192503?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2010-09. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01192503?
The interventions under investigation include: rasagiline (DRUG), placebo (sugar pill) (DRUG).
Who is sponsoring clinical trial NCT01192503?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01192503's enrollment target sits among peer trials
52 1181st of 2000 higher than 811 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia